Literature DB >> 24140545

Further experimentation of inhaled; LANTUS, ACTRAPID and HUMULIN with todays' production systems.

Paul Zarogoulidis1, Dimitris Petridis, Christos Ritzoulis, Qiang Li, Haidong Huang, Yunye Ning, Kaid Darwiche, Lutz Freitag, Konstantinos Zarogoulidis.   

Abstract

BACKGROUND: Several aerosol production systems have been used for aerosol insulin production. However; since the first studies several new models of jet-nebulizers and ultrasound nebulizers have been introduced in the market.
MATERIALS AND METHODS: Three different models of jet-nebulizers (different brands, same properties) and three different ultrasound nebulizers (different brands, same properties). Six residual cups (2 small ≤ 6 ml and 3 large ≤ 8 ml) were used for the jet-nebulizers. The ultrasound nebulizers were used with their facemasks or with their inlets which were included in the purchase package.
RESULTS: Ultrasound nebulizers; LANTUS produces by far the lowest mean droplets (2.44) half the size of the other two drugs (4.43=4.97). GIMA nebulizer is the most efficient producing one third of the droplet size of SHIMED and one second of EASYNEB (2.06<3.15<6.62). Finally, the 4 ml loading concentration is more suitable for supporting the production of smaller droplets (3.65<4.24). Drugs and nebulizers act interactively yielding very large droplets when ACTRAPID and HUMULIN are administered in joint with SHIMED nebulizer (9.59=7.72). Jet-nebulizers; HUMULIN again is the least preferred insulin since it hardly reaches the low but equal performance of others at the loading level of 6 ml. Residual cups E and B produce uniquely lower mean droplets at loading level 6.
CONCLUSIONS: Ultrasound nebulizers; the best suggested combination should be LANTUS insulin, GIMA nebulizer administered at loading dose of 4 ml jet-nebulizers. A global review can give the best combination: the lowest mean droplets are produced when the drugs LANTUS (mostly) and ACTRAPID are administered, applying the SUNMIST nebulizer in concert with residual cup B at loading levels of 6 ml.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Actrapid (PubChem SID: 135350514); Aerosol insulin; Carboplatin (PubChem CID: 10339178); Cisplatin (PubChem CID: 84093); Docetaxel (PubChem CID: 148124); Doxorubicin (PubChem CID: 31703); Gemcitabine (PubChem CID: 60750); Humulin Regular (PubMed CID: 16129672); Jet-nebulizers; Lantus (PubChem CID: 44146714); Paclitaxel (PubChem CID: 36314); Tobramycin (PubChem CID: 36294); Ultrasound

Mesh:

Substances:

Year:  2013        PMID: 24140545     DOI: 10.1016/j.ijpharm.2013.10.019

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.

Authors:  Haidong Huang; Paul Zarogoulidis; Sofia Lampaki; John Organtzis; Dimitris Petridis; Konstantinos Porpodis; Antonis Papaiwannou; Vasilis Karageorgiou; Georgia Pitsiou; Ioannis Kioumis; Wolfgang Hohenforst-Schmidt; Qiang Li; Kaid Darwiche; Lutz Freitag; Aggeliki Rapti; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Dionysios Spyratos; Georgia Pitsiou; Dimitris Petridis; Athanasia Pataka; Haidong Huang; Qiang Li; Lonny Yarmus; Wolfgang Hohenforst-Schmidt; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-08-12       Impact factor: 4.162

3.  Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.

Authors:  Georgia Pitsiou; Paul Zarogoulidis; Dimitris Petridis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Wolfgang Hohenforst-Schmidt; Stylianos Kakolyris; Konstantinos Syrigos; Haidong Huang; Qiang Li; J Francis Turner; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-10-07       Impact factor: 4.162

4.  Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Bernd Linsmeier; Ioannis Kioumis; Qiang Li; Haidong Huang; Despoina Sachpatzidou; Sofia Lampaki; John Organtzis; Kalliopi Domvri; Leonidas Sakkas; George A Zachariadis; Konstantinos N Archontas; Anastasios Kallianos; Aggeliki Rapti; Lonny Yarmus; Konstantinos Zarogoulidis; Johannes Brachmann
Journal:  J Cancer       Date:  2014-03-24       Impact factor: 4.207

5.  Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination.

Authors:  Konstantinos Sapalidis; Paul Zarogoulidis; Efstathios Pavlidis; Stella Laskou; Athanasios Katsaounis; Charilaos Koulouris; Dimitrios Giannakidis; Stylianos Mantalovas; Haidong Huang; Chong Bai; Yuting Wen; Li Wang; Chrysanthi Sardeli; Aikaterini Amaniti; Ilias Karapantzos; Chrysanthi Karapantzou; Wolfgang Hohenforst-Schmidt; Fotis Konstantinou; Isaak Kesisoglou; Naim Benhanseen
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207

6.  Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible.

Authors:  Konstantinos Sapalidis; Paul Zarogoulidis; Haidong Huang; Chong Bai; Yuting Wen; Li Wang; Konstantina Boniou; Ilias Karapantzos; Chrysanthi Karapantzou; Michael Karanikas; Vasilis Thomaidis; Christoforos Kosmidis; Chrysanthi Sardeli; Naim Benhassen; Yan-Gao Man; Maria C Florou; Stylianos Mantalovas; Stella Laskou; Dimitris Giannakidis; Charilaos Koulouris; Aikaterini Amaniti; Isaak Kesisoglou; Wolfgang Hohenforst-Schmidt
Journal:  J Cancer       Date:  2018-03-02       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.